Nytteeffekt av avanserte MR-metoder i brystkreftbehandling
- Prosjektnummer
- 46021800
- Ansvarlig person
- Steinar Lundgren
- Institusjon
- NTNU, ISB
- Prosjektkategori
- Forskerstipend 2008
- Helsekategori
- Cancer
- Forskningsaktivitet
- 6. Treatment Evaluation
Monitoring neoadjuvant chemotherapy in breast cancer patients: Improved MR assessment at 3 T?
J Magn Reson Imaging 2011 Jul. Epub 2011 jul 14
PMID: 21761463
In vivo MRS of locally advanced breast cancer: characteristics related to negative or positive choline detection and early monitoring of treatment response.
MAGMA 2011 Dec;24(6):347-57. Epub 2011 sep 10
PMID: 21909791
Diffusion-weighted and dynamic contrast-enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients.
J Magn Reson Imaging 2011 Nov;34(5):1099-109. Epub 2011 aug 23
PMID: 22002757
Relative biological effectiveness of photon energies used in brachytherapy and intraoperative radiotherapy techniques for two breast cancer cell lines.
Acta Oncol 2010 Nov;49(8):1261-8. Epub 2010 aug 25
PMID: 20735284
Merging transcriptomics and metabolomics--advances in breast cancer profiling.
BMC Cancer 2010;10():628. Epub 2010 nov 16
PMID: 21080935
Monitoring the Effect of Docetaxel Treatment in MCF7 Xenografts Using Multimodal In Vivo and Ex Vivo Magnetic Resonance Methods, Histopathology, and Gene Expression.
Transl Oncol 2010;3(4):252-63. Epub 2010 aug 1
PMID: 20689767
Prognostic value of pretreatment dynamic contrast-enhanced MR imaging in breast cancer patients receiving neoadjuvant chemotherapy: overall survival predicted from combined time course and volume analysis.
Acta Radiol 2010 Jul;51(6):604-12.
PMID: 20429756
Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics.
J Proteome Res 2010 Feb;9(2):972-9.
PMID: 19994911
Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial.
Lancet 2010 Jul;376(9735):91-102.
PMID: 20570343
Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy.
NMR Biomed 2010 May;23(4):424-31. Epub 2010 jan 25
PMID: 20101607
Assessment of early docetaxel response in an experimental model of human breast cancer using DCE-MRI, ex vivo HR MAS, and in vivo 1H MRS.
NMR Biomed 2010 Jan;23(1):56-65.
PMID: 19650073
Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI.
J Magn Reson Imaging 2009 Jun;29(6):1300-7.
PMID: 19472387
Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype.
PLoS One 2009;4(8):e6554. Epub 2009 aug 7
PMID: 19662092
Gene expression profiling and pathway analysis of superficial bladder cancer in rats.
Urology 2010 Mar;75(3):742-9. Epub 2009 aug 3
PMID: 19647301
CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.
PLoS ONE 2008;3(8):e3062. Epub 2008 aug 26
PMID: 18725978
Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
Lung Cancer 2008 Aug;61(2):235-43. Epub 2008 feb 20
PMID: 18281122
Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism.
Ann Oncol 2008 Jan;19(1):56-61. Epub 2007 okt 18
PMID: 17947222
Outcome of whole-brain irradiation for breast cancer patients.
Acta Oncol 2008;47(2):261-6.
PMID: 17882559
Adjuvant cyclic Tamoxifen and Megestrol acetate treatment in postmenopausal breast cancer patients--longterm follow-up.
Eur J Surg Oncol 2008 Jan;34(1):6-12. Epub 2007 sep 18
PMID: 17881183
Characterization of brain metastases using high-resolution magic angle spinning MRS.
NMR Biomed 2008 Feb;21(2):175-85.
PMID: 17542042
Is there a correlation between DCE-MRI and survival?
Eur Radiology 2009; 19:suppl 4:s826-s829
Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy.
NMR Biomed Epub 2009
Multivariate Modeling and Prediction of Breast Cancer Prognostic Factors Using MR Metabolomics.
J Proteome Res Epub 2009
Assessment of early docetaxel response in an experimental model of human breast cancer using DCE-MRI, ex vivo HR MAS, and in viv
NMR Biomed , e-publ (Publmed) 2009
Tissue metabolic concentrations investigated with respect to prognosis for breast cancer patients
ISMRM Congress; 2009, Hawaii. Conference proceedings
Evaluation of vascular and metabolic response in a human breast cancer model treated with docetaxel.
ISMRM Congress; 2009, Hawaii. Conference proceedings
Diffusion measurements in advanced breast cancer – reproducibility and changes after treatment.
ESMRMB 2009 Annual Congress;Turkey. Conference proceedings
Dynamic contrast-enhanced magnetic resonance imaging reveals differences in xenografts with luminal like and basal like gene exp
ESMRMB 2009 Annual Congress;Turkey. Conference proceedings
Multiparametric MRI/MRS and gene expression profiling for monitoring docetaxel effects in MCF7 xenografts.
ISMRM Congress; 2009, Hawaii. Conference proceedings
In vivo and ex vivo choline metabolite profiles as biomarkers for treatment response in locally advanced breast cancer
ISMRM Congress; 2009, Hawaii. Conference proceedings
Classification and prediction of prognostic factors of breast cancer patients by MR metabolomics.
ISMRM Congress; 2009, Hawaii. Conference proceedings
Choline metabolites as biomarkers for predicting response to neoadjuvant chemotherapy in local advanced breast cancer patients.
ISMRM Congress; 2009, Hawaii. Conference proceedings
MR metabolomics – a tool in detection of biomarkers for response to neoadjuvant chemotherapy in local advanced breast cancer?.
ESMRMB 2009 Annual Congress;Turkey. Conference proceedings
Simple classification ofcontrast enhancement curves in DCE MRI correlates to breast cancer survival.
Poster presentasjon ISMRM, Toronto Mai 2008
Evaluation of early docetaxel effects in MCF7 xenografts using HR MAS, in vivo MRS, DCE-MRI and ADC-mapping.
Poster presentasjon ISMRM mai 2008
DCE-MRI assessment of neoadjuvant chemotherapy and clinical outcome in locally advanced breast cancer patients.
Poster presentasjon ISMRM, Toronto Mai 2008
Prediction of long term breast cancer survival using MR metabolomics. In vivo and ex vivo choline metabolite profiles as biomark
Forelesning ISMRM mai 2008
In vivo and ex vivo choline metabolite profiles as biomarkers for treatment response in locally advanced human breast cancer
Abstrakter innsendt til ISMRM 2009, 18.-24. april, godkjent som poster
Multiparametric MRI/MRS and gene expression profiling for monitoring docetaxel effects in MCF7 xenografts.
Abstrakter innsendt til ISMRM 2009, 18.-24. april, godkjent som poster
Combining data from HR MAS MR spectroscopy and gene expression can refine the subclassification of breast cancer
Abstrakter innsendt til ISMRM 2009, 18.-24. april, godkjent som poster
Choline metabolites as biomarkers for predicting response to neoadjuvant chemotherapy in local advanced breast cancer patients.
Abstrakter innsendt til ISMRM 2009, 18.-24. april, godkjent som forelesning
Subclassification of brain tumors based on ex vivo MRS metabolic profiles.
Abstrakter innsendt til ISMRM 2009, 18.-24. april, godkjent som poster
Classification and prediction of prognostic factors of breast cancer patients by MR metabolomics.
Abstrakter innsendt til ISMRM 2009, 18.-24. april, godkjent som poster
Tissue metabolic concentrations investigated with respect to prognosis for breast cancer patients.
Abstrakter innsendt til ISMRM 2009, 18.-24. april, godkjent som poster
Genome-wide profile of pleural mesothelium versus parietal and visceral pleura: Differential gene expression reflects aggressiv
Innsendt 2008 for publisering
Gene expression reflecting resistance and new targets in mesothelioma: a general model of tumor resistance?
Innsendt 2008 for publisering
Predicting 5 years survival for breast cancer patients using dynamic contrast enhanced MRI.
Poster presentasjon ISMRM mai 2008
Choline profiles of breast cancer correlate to clinical characteristics.
Poster presentasjon ISMRM mai 2008
Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using D
Accepted JMRI
Prognostic value of pre-treatment dynamic contrast-enhanced MR imaging in locally advanced breast cancer: overall survival predi
Sendes Radiology februar 2009
Relative biological effectiveness on breast cancer cell lines of photon energies and dose rates used in external and intraoperat
Skal sendes inn februar 2009
Clinical application of multimodal magnetic resonance imaging
- Disputert:
- februar 2011
- Hovedveileder:
- Asta K. Håberg
Identification and characterization of prognostic factors in breast cancer using MR metabolomics
- Disputert:
- desember 2011
- Hovedveileder:
- Tone F. Bathen og Ingrid S. Gribbestad
Evaluation of neoadjuvant chemotherapy in locally advanced breast cancer based on MR methodology
- Disputert:
- juni 2011
- Hovedveileder:
- Tone F. BathIngrid S Gribbestad, Steinar lundgren, Pål Erik Goa
Evaluation of treatment effects in cancer by MR imaging and spectroscopy
- Disputert:
- mars 2010
- Hovedveileder:
- Ingrid S. Gribbestad
MR evaluation of breast cancer patients with poor prognosis
- Disputert:
- oktober 2010
- Hovedveileder:
- Steinar Lundgren
Assessment of tumor microenvironment and treatment effects in human breast cancer xenografts using MR imaging and spevtroscopy
- Disputert:
- november 2010
- Hovedveileder:
- Ingrid S. Gribbestad
Malignant mesothelioma: Virus, biomarkers and genes - a translational approach
- Disputert:
- oktober 2008
- Hovedveileder:
- Steinar Lundgren og Erik Larsson
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Helse Midt-Norge RHF - Samarbeidsorganet og FFU